Table 2

Clinical characteristics of patients with each gene alteration in primary ovarian cancer

CaseAge (yrs)HistologyaClinical stageWestern blot of p53Western blot of TGF-β RILOH analysis of TGF-β RIFrameshift mutation of TGF-β RISequence change of TGF-β RIISequence change of Smad2
153Serous2C++Intron 2 (A)
217Dysgerminoma1A++Intron 2 (A)T18 → T16
346Serous4++Intron 2 (G)T18 → T16
447Serous3A++Intron 2 (G)T18 → T16
546Mucinous1A++Intron 2 (G)T18 → T16
630Mucinous1A++Intron 2 (A)
754Endometrioid3C++Intron 2 (A)T18 → T16
839Endometrioid1C++Intron 2 (A)
934Clear cell3C++Intron 2 (A/G)
1048Clear cell4++Intron 2 (G)
1168Serous3C++Intron 2 (G)
1248Clear cell2C+++Intron 2 (A)T18 → T16
1328Dermoid (malignant)1A++Intron 2 (A/G)
1468Poorly differentiated adenocarcinoma3C++Intron 2 (A/G)
1547Serous1A++Intron 2 (A/G)
1682Mucinous (LPM)1A++Intron 2 (A)
1773Mucinous3A++Intron 2 (A)T18 → T16
1843Serous3C++Intron 2 (A)
1964Normal++Intron 2 (A/G)
Serous3C++Intron 2 (A/G)
2058Normal++Intron 2 (A/G)
Mucinous1A++Intron 2 (A/G)T18 → T16
2168Normal++Intron 2 (G)
Serous3C++Intron 2 (G)T18 → T16
2255Normal++Intron 2 (A/G)
Endometrioid1A++Intron 2 (A/G)
2359Normal+++Intron 2 (A/G)
Clear cell1C+Intron 2 (A/G)
2453Normal++Intron 2 (A)
Clear cell3C++Intron 2 (A)T18 → T16
2560Normal++Intron 2 (A)
Mucinous1A++Intron 2 (A)T18 → T16
2658Normal++Intron 2 (A/G)
Serous3C++Intron 2 (A/G)
2754Normal++Intron 2 (A/G)
Mucinous (LPM)1C++Intron 2 (A/G)
2857Normal+++Intron 2 (G)
Serous3B++Intron 2 (G)
2955Normal++Intron 2 (G)
Serous1A++Intron 2 (G)
3052Normal++Intron 2 (A/G)
Clear cell1A++Intron 2 (A/G)T18 → T16
3163Normal++Intron 2 (A)
Serous3C++Intron 2 (A)
3261Normal++Intron 2 (A/G)
Serous3C++Intron 2 (A/G)
  • a Serous, serous cystadenocarcinoma; mucinous, mucinous cystadenocarcinoma; endometrioid, endometrioid adenocarcinoma; clear cell, clear cell adenocarcinoma; LPM, low potential malignancy.